The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are degraded by dipeptidyl peptidase IV (DPP IV), thereby losing insulinotropic activity. DPP IV inhibition reduces exogenous GLP-1 degradation, but the extent of endogenous incretin protection has not been fully assessed, largely because suitable assays which distinguish between intact and degraded peptides have been unavailable. Using newly developed assays for intact GLP-1 and GIP, the effect of DPP IV inhibition on incretin hormone metabolism was examined. Conscious dogs were given NVP-DPP728, a specific DPP IV inhibitor, at a dose that inhibited over 90% of plasma DPP IV for the first 90 min following treatment. Total and intact incretin concentrations increased (P<0.0001) following a mixed meal, but on control days (vehicle infusion), intact peptide concentrations were lower (P<0.01) than total peptide concentrations (22.6 +/- 1.2% intact GIP; 10.1 +/- 0.4% intact GLP-1). Following inhibitor treatment, the proportion of intact peptide increased (92.5 +/- 4.3% intact GIP, P<0.0001; 99.0 +/- 22.6% intact GLP-1, P<0.02). Active (intact) incretins increased after NVP-DPP728 (from 4797 +/- 364 to 10 649 +/- 106 pM x min for GIP, P<0.03; from 646 +/- 134 to 2822 +/- 528 pM x m in for GLP-1, P<0.05). In contrast, total incretins fell (from 21 632 +/- 654 to 12 084 +/- 1723 pM x min for GIP, P<0.002; from 5145 +/- 677 to 3060 +/- 601 pM x min for GLP-1, P<0.05). Plasma glucose, insulin and glucagon concentrations were unaltered by the inhibitor. We have concluded that DPP IV inhibition with NVP-DPP728 prevents N-terminal degradation of endogenous incretins in vivo, resulting in increased plasma concentrations of intact, biologically active GIP and GLP-1. Total incretin secretion was reduced by DPP IV inhibition, suggesting the possibility of a feedback mechanism.

This article has been cited by other articles:

				Y. Kirino, Y. Sato, T. Kamimoto, K. Kawazoe, K. Minakuchi, and Y. Nakahori Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats J. Endocrinol., January 1, 2009; 200(1): 53 - 61. [Abstract] [Full Text] [PDF]

				A. El-Ouaghlidi, E. Rehring, J. J. Holst, A. Schweizer, J. Foley, D. Holmes, and M. A. Nauck The Dipeptidyl Peptidase 4 Inhibitor Vildagliptin Does Not Accentuate Glibenclamide-Induced Hypoglycemia but Reduces Glucose-Induced Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide Secretion J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4165 - 4171. [Abstract] [Full Text] [PDF]

				J. J. Holst The Physiology of Glucagon-like Peptide 1 Physiol Rev, October 1, 2007; 87(4): 1409 - 1439. [Abstract] [Full Text] [PDF]

				L. Simonsen, S. Pilgaard, C. Orskov, M. M. Rosenkilde, B. Hartmann, J. J. Holst, and C. F. Deacon Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G288 - G295. [Abstract] [Full Text] [PDF]

				B. Ahren Dipeptidyl Peptidase-4 Inhibitors: Clinical data and clinical implications Diabetes Care, June 1, 2007; 30(6): 1344 - 1350. [Full Text] [PDF]

				T. Vilsboll and F. K Knop Review: DPP IV inhibitors - current evidence and future directions The British Journal of Diabetes & Vascular Disease, March 1, 2007; 7(2): 69 - 74. [Abstract] [PDF]

				G. A. Herman, A. Bergman, C. Stevens, P. Kotey, B. Yi, P. Zhao, B. Dietrich, G. Golor, A. Schrodter, B. Keymeulen, et al. Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4612 - 4619. [Abstract] [Full Text] [PDF]

				V. Ionut, I. F. Liberty, K. Hucking, M. Lottati, D. Stefanovski, D. Zheng, and R. N. Bergman Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action Am J Physiol Endocrinol Metab, October 1, 2006; 291(4): E779 - E785. [Abstract] [Full Text] [PDF]

				C. F. Deacon, A. Plamboeck, M. M. Rosenkilde, J. de Heer, and J. J. Holst GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E468 - E475. [Abstract] [Full Text] [PDF]

				B. F. Burkey, X. Li, L. Bolognese, B. Balkan, M. Mone, M. Russell, T. E. Hughes, and P. R. Wang Acute and Chronic Effects of the Incretin Enhancer Vildagliptin in Insulin-Resistant Rats J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 688 - 695. [Abstract] [Full Text] [PDF]

				A. Mari, W. M. Sallas, Y. L. He, C. Watson, M. Ligueros-Saylan, B. E. Dunning, C. F. Deacon, J. J. Holst, and J. E. Foley Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed {beta}-Cell Function in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4888 - 4894. [Abstract] [Full Text] [PDF]

				B. D Green, N. Irwin, V. A Gault, F. P. O'Harte, and P. R Flatt Review: Development and therapeutic potential of incretin hormone analogues for type 2 diabetes The British Journal of Diabetes & Vascular Disease, May 1, 2005; 5(3): 134 - 140. [Abstract] [PDF]

				A. K. Bose, M. M. Mocanu, R. D. Carr, C. L. Brand, and D. M. Yellon Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury Diabetes, January 1, 2005; 54(1): 146 - 151. [Abstract] [Full Text] [PDF]

				J. J. Holst and C. Orskov The Incretin Approach for Diabetes Treatment: Modulation of Islet Hormone Release by GLP-1 Agonism Diabetes, December 1, 2004; 53(suppl_3): S197 - S204. [Abstract] [Full Text] [PDF]

				C. F. Deacon Therapeutic Strategies Based on Glucagon-Like Peptide 1 Diabetes, September 1, 2004; 53(9): 2181 - 2189. [Abstract] [Full Text] [PDF]

				J. J. Meier, M. A. Nauck, D. Kranz, J. J. Holst, C. F. Deacon, D. Gaeckler, W. E. Schmidt, and B. Gallwitz Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects Diabetes, March 1, 2004; 53(3): 654 - 662. [Abstract] [Full Text] [PDF]

				M. Nishizawa, M. C. Moore, M. Shiota, S. M. Gustavson, W. L. Snead, D. W. Neal, and A. D. Cherrington Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E1027 - E1036. [Abstract] [Full Text] [PDF]